AstraZeneca - Publications - Faculty & Research

September 2014 (Revised February 2015)
Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details

Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States

Citation

Educators

Purchase

January 2014
Teaching Plan

MedImmune Ventures

By: Richard Hamermesh and Andrew Otazo

"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details

Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States

Citation

Purchase

August 2013 (Revised October 2013)
Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane

Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details